News | June 04, 2006

Label Affirms No Increased Heart Attack Risk

The FDA has approved revised labeling for the instructions for use of the CYPHER Sirolimus-eluting Coronary Stent. The labeling now reflects FDA's review of clinical trial data that suggests there is no increased risk of myocardial infarction with the use of overlapping CYPHER Stents in comparison to bare metal stents.
The change is based on a retrospective analysis of several clinical studies of overlapping CYPHER Stents examining more than 900 patients. Cypher is the only drug-eluting stent with this new label.
Overlapping stents are most often used in patients with complex coronary artery disease in which the blockage is too long for a single stent. Today, approximately 25 percent of stenting procedures involve the use of overlapping coronary stents.

Related Content

Coronary and Peripheral Stent Market Expected to Double Through 2025
News | Stents | May 28, 2020
May 28, 2020 — The rising incidence of cardiovascular disease has prompted people to seek timely treatment to improve
The Boston Scientific Synergy stent uses a unique abluminal, bioresorbable drug-carrier polymer that dissolves after the vessel wall has healed months after the stent is implanted. Stent polymers have been implicated in cases of late-stent thrombosis, which required patients with DES to stay on dual antiplatelet therapy (DAPT). This study looked at using the device as a way to shorten DAPT duration. #SCAI2020

The Boston Scientific Synergy stent uses a unique abluminal, bioresorbable drug-carrier polymer that dissolves after the vessel wall has healed months after the stent is implanted. Stent polymers have been implicated in cases of late-stent thrombosis, which required patients with DES to stay on dual antiplatelet therapy (DAPT). This study looked at using the device as a way to shorten DAPT duration.

News | Stents | May 17, 2020
May 17, 2020 – A new study sought to reveal whether drug-eluting stents (DES) coated with bioabsorbable polymer (BP)
Biotronik announced three-year data from the BIOFLOW-V Trial, which was presented yesterday at the 2020 Cardiovascular Research Technologies (CRT) Congress. The three-year follow-up data demonstrates consistently lower clinical event rates and improvement in patient outcomes, reinforcing the differentiation of the Orsiro coronary drug-eluting stent (DES), which is the first DES to outperform Xience.
News | Stents | February 24, 2020
February 24, 2020 — Biotronik announced three-year data from the...
The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.

The Boston Scientific Eluvia self-expanding, drug-eluting, peripheral stent.

Feature | Stents | February 11, 2020 | Saloni Walimbe
Cardiovascular diseases (CVDs) are among the leading causes of death across the globe.
Global Cardiovascular Stent Market Poised for Almost 7 Percent Growth Through 2025
News | Stents | August 21, 2019
Increasing incidence of cardiovascular diseases worldwide is creating growth opportunities for the global...
The U.S. Food and Drug Administration (FDA) recently granted an additional indication to Bard Peripheral Vascular's Covera Vascular Covered Stent for the treatment of a stenosis or blockage which has developed anywhere in the access circuit of patients on hemodialysis using an arteriovenous (AV) fistula.
Technology | Stents | April 03, 2019
April 3, 2019 — The U.S.

A comparison of stent strut thickness between the Orsiro stent, pictured, and the market-leading stents on the U.S. and European markets. Vendors have been working toward reducing strut thickness to help improve overall clinical outcomes. Orsiro is now the smallest strut stent available on the market. 

Feature | Stents | February 22, 2019 | Dave Fornell, Editor
February 22, 2019 — The U.S.
The Medtronic Resolute Integrity drug-eluting stent is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data. Stent advances and new stent technologies.

The Medtronic Resolute Integrity drug-eluting stent (DES) is among the top three stents on the U.S. market. Outcomes for these stents are very similar, so the stents have largely become a commodity product purchased on price rather than clinical data.

Feature | Stents | January 29, 2019 | Dave Fornell, Editor
There was a lot of hype and high hopes pinned on bioresorbable stent technologies as the way of the future two years
The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

The Indian-made SMT SuperFlex stent. SMT has been developing stents and other interventional products designed to be a more affordable, home-grown option for the growing Indian market.

News | Stents | January 22, 2019
The rise cardiovascular disease has been instrumental in fueling the coronary stent market share in the past few year
The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent. #TCT2018

The Biotronik Osiro is an ultra thin strut, sirolimus-eluting stent.

News | Stents | October 04, 2018
October 4, 2018 – Investigators unveiled clinical data from the independent BIONYX and SORT OUT IX all-comers trials